5 million and growing: scaling Granudacyn® production in Salzburg
Mölnlycke® has reached a significant milestone with the production of 5 million units of its Granudacyn® wound irrigation solution at its manufacturing site in Salzburg, Austria, reflecting strong and sustained global demand for advanced wound cleansing solutions.
“The consistent growth we’ve seen for Granudacyn® enables us to take a long-term, targeted approach to expanding our manufacturing capacity,” said Kevin Sands, General Manager of the Salzburg site. “By optimising processes, investing in equipment and applying lean principles, we are increasing output while maintaining the highest standards of quality and reliability.”
Mölnlycke acquired the Salzburg factory in October 2024 after more than five years of collaboration with its previous owners. Since then, it has been successfully integrated into Mölnlycke’s global manufacturing network of 16 sites in 11 countries, with investments in systems, operational excellence and cross-functional collaboration driving greater efficiency, scalability and growth.
Granudacyn® is a biocompatible, non-cytotoxic wound irrigation solution designed to safely cleanse, irrigate and moisten a wide range of acute, chronic and contaminated wounds. Using hypochlorous acid-based technology, it supports wound healing while ensuring microbial purity of the solution and ease of use. The product is suitable for a broad range of indications, including pressure injuries, leg and foot ulcers, burns (1st and 2nd degree) and surgical wounds.
Today, Granudacyn® is available in 54 markets worldwide, having expanded significantly beyond its European origins. Commercial momentum continues to build and, following FDA clearance, Granudacyn® is now being introduced in the United States, with further market expansion planned.
“Granudacyn® plays an important role in opening up broader conversations around modern wound care and our wider portfolio,” said Giuseppe Conti, Global Product Manager for Granudacyn®. “Its flexibility across multiple wound types, combined with strong clinical confidence, has driven adoption across a growing number of markets.”
With production continuing to scale, Mölnlycke remains committed to supporting healthcare professionals worldwide with reliable access to high-quality wound care solutions that reduce the burden of wounds, improve patient outcomes and enhance clinical efficiency.
Latest news
-
Mölnlycke improves overall score in 2026 EcoVadis sustainability assessment
Mölnlycke has further strengthened its sustainability performance in the latest EcoVadis assessment, achieving a ranking in the 98th percentile.
-
Dartford and Gravesham NHS Trust adopts Steriwave to support infection prevention
Dartford and Gravesham NHS Trust in the UK has adopted Steriwave® nasal photodisinfection for elective orthopaedic surgery, working with Mölnlycke and Ondine Biomedical to strengthen its approach to surgical site infection prevention.
-
New leaders appointed for Mölnlycke Health Care
Gothenburg, Sweden. 3 November 2026. Mölnlycke® announces the appointment of Anders Andersson as Chief Executive Officer (CEO) of Mölnlycke Health Care and Fredrik Wallefors as President of Surgical, effective 1 January 2027.
-
Mölnlycke Health Care announces new partnership with DEBRA International to help advance wound care for the EB community
Mölnlycke is partnering with DEBRA International, the world’s leading epidermolysis bullosa (EB) patient advocacy network, to deepen understanding of the needs of people living with EB and help advance wound care for the global EB community.
-
Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
-
Martin Ma joins Mölnlycke Zhende as General Manager
In this role, Martin will lead the joint venture's operations and growth strategy in China, with responsibility for commercial execution, organisational leadership, governance and delivery of growth ambitions in one of the world's largest wound care markets.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold strategic partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.